These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
840 related articles for article (PubMed ID: 31915054)
1. Systematic review and meta-analysis protocol for efficacy and safety of Momordica charantia L. on animal models of type 2 diabetes mellitus. Peter EL; Mtewa AG; Nagendrappa PB; Kaligirwa A; Sesaazi CD Syst Rev; 2020 Jan; 9(1):7. PubMed ID: 31915054 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of Momordica charantia Linnaeus in pre-diabetes and type 2 diabetes mellitus patients: a systematic review and meta-analysis protocol. Peter EL; Deyno S; Mtewa A; Kasali FM; Nagendrappa PB; Sesaazi D; Tolo CU; Ogwang PE Syst Rev; 2018 Nov; 7(1):192. PubMed ID: 30442186 [TBL] [Abstract][Full Text] [Related]
3. Momordica charantia L. lowers elevated glycaemia in type 2 diabetes mellitus patients: Systematic review and meta-analysis. Peter EL; Kasali FM; Deyno S; Mtewa A; Nagendrappa PB; Tolo CU; Ogwang PE; Sesaazi D J Ethnopharmacol; 2019 Mar; 231():311-324. PubMed ID: 30385422 [TBL] [Abstract][Full Text] [Related]
4. Momordica charantia for type 2 diabetes mellitus. Ooi CP; Yassin Z; Hamid TA Cochrane Database Syst Rev; 2010 Feb; (2):CD007845. PubMed ID: 20166099 [TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
6. Momordica charantia for type 2 diabetes mellitus. Ooi CP; Yassin Z; Hamid TA Cochrane Database Syst Rev; 2012 Aug; (8):CD007845. PubMed ID: 22895968 [TBL] [Abstract][Full Text] [Related]
7. The safety and efficacy of Momordica charantia L. in animal models of type 2 diabetes mellitus: A systematic review and meta-analysis. Peter EL; Nagendrappa PB; Kaligirwa A; Ogwang PE; Sesaazi CD Phytother Res; 2021 Feb; 35(2):637-656. PubMed ID: 32929814 [TBL] [Abstract][Full Text] [Related]
8. The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. Dans AM; Villarruz MV; Jimeno CA; Javelosa MA; Chua J; Bautista R; Velez GG J Clin Epidemiol; 2007 Jun; 60(6):554-9. PubMed ID: 17493509 [TBL] [Abstract][Full Text] [Related]
9. Bioactives of Xu B; Li Z; Zeng T; Zhan J; Wang S; Ho CT; Li S Molecules; 2022 Mar; 27(7):. PubMed ID: 35408574 [No Abstract] [Full Text] [Related]
10. Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus. Kim SK; Jung J; Jung JH; Yoon N; Kang SS; Roh GS; Hahm JR Complement Ther Med; 2020 Aug; 52():102524. PubMed ID: 32951763 [TBL] [Abstract][Full Text] [Related]
11. Suppressive activity of the fruit of Momordica charantia with exercise on blood glucose in type 2 diabetic mice. Miura T; Itoh Y; Iwamoto N; Kato M; Ishida T Biol Pharm Bull; 2004 Feb; 27(2):248-50. PubMed ID: 14758046 [TBL] [Abstract][Full Text] [Related]
12. Effects of Momordica Charantia (Karela/bitterguord) in Type 2 Diabetic Patients Taking Allopathic Drugs: A pilot study. Rauniyar GP; Sinha R; Chapagain K; Maskey R; Pandey DR Kathmandu Univ Med J (KUMJ); 2021; 19(74):143-147. PubMed ID: 34819444 [TBL] [Abstract][Full Text] [Related]
13. Effects of dietary wild bitter melon (Momordica charantia var. abbreviate Ser.) extract on glucose and lipid metabolism in HFD/STZ-induced type 2 diabetic rats. Sun K; Ding M; Fu C; Li P; Li T; Fang L; Xu J; Zhao Y J Ethnopharmacol; 2023 Apr; 306():116154. PubMed ID: 36634725 [TBL] [Abstract][Full Text] [Related]
14. In vivo hypoglycemic effect of methanolic fruit extract of Momordica charantia L. Nkambo W; Anyama NG; Onegi B Afr Health Sci; 2013 Dec; 13(4):933-9. PubMed ID: 24940315 [TBL] [Abstract][Full Text] [Related]
15. Potential for improved glycemic control with dietary Momordica charantia in patients with insulin resistance and pre-diabetes. Efird JT; Choi YM; Davies SW; Mehra S; Anderson EJ; Katunga LA Int J Environ Res Public Health; 2014 Feb; 11(2):2328-45. PubMed ID: 24566057 [TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms of organic cation transporters 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes mellitus: a systematic review protocol. Mato EPM; Guewo-Fokeng M; Faadiel Essop M; Owira PMO Syst Rev; 2018 Jul; 7(1):105. PubMed ID: 30041690 [TBL] [Abstract][Full Text] [Related]
17. Bitter melon (Momordica charantia): a review of efficacy and safety. Basch E; Gabardi S; Ulbricht C Am J Health Syst Pharm; 2003 Feb; 60(4):356-9. PubMed ID: 12625217 [TBL] [Abstract][Full Text] [Related]
18. The Effects of Richter E; Geetha T; Burnett D; Broderick TL; Babu JR Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902074 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of artemisinin and its derivatives in animal models of type 2 diabetes mellitus: A systematic review and meta-analysis. Wu T; Feng H; He M; Yue R; Wu S Pharmacol Res; 2022 Jan; 175():105994. PubMed ID: 34808366 [TBL] [Abstract][Full Text] [Related]
20. Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review. Leung L; Birtwhistle R; Kotecha J; Hannah S; Cuthbertson S Br J Nutr; 2009 Dec; 102(12):1703-8. PubMed ID: 19825210 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]